Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Sanofi SA News

    91,76 € -0,10% -0,09 €
    29.04.24 21:50:44 Tradegate aktualisieren | Orderbuch | Mehr Kurse »
    WKN: 920657
    ISIN: FR0000120578
    US-Symbol: SNYNF
    Typ: Aktie
    Werbung

    Attraktive Knock-Outs auf Sanofi SA

    Typ Hebel Bid / Ask WKN
    Call
    		4,9 1,84 € / 1,87 €
    SN5672
    Call
    		9,6 0,94 € / 0,97 €
    SN567W
    Typ Hebel Bid / Ask WKN
    Put
    		5,0 1,83 € / 1,86 €
    SH4RDM
    Put
    		11,8 0,76 € / 0,79 €
    SU44A5
    Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
    Alle Knock-Outs auf Sanofi SA
    Werbung
    Weiter abwärts?
    Short Hebel 5,29
    ME2BPF

    Unternehmensmeldungen

    19.10.23 - GlobeNewswire
    Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio
    Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio
    04.10.23 - GlobeNewswire
    Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
    01.12.22 - DGAP
    Form 8.3 - The Vanguard Group, Inc.: Sanofi
    The Vanguard Group, Inc. ( IRSH) Form 8.3 - The Vanguard Group, Inc.: Sanofi 01-Dec-2022 / 15:09 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS ...
    28.04.22 - GlobeNewswire
    Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1
    Sanofi continues to deliver strong business EPS ( 1) growth driven by higher sales and improved margins in Q1
    23.02.22 - GlobeNewswire
    Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
    Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine * Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- ...
    04.02.22 - GlobeNewswire
    Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R&D
    Strong 2021 sales and business EPS (1) growth enabling increased investment in R&D
    03.02.22 - GlobeNewswire
    Press Release: Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity
    Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity
    16.04.21 - DGAP
    Morgan Stanley Europe SE: Stabilisation Notice
    DGAP-News: Morgan Stanley Europe SE / Key word(s): Miscellaneous Morgan Stanley Europe SE: Stabilisation Notice 16.04.2021 / 16:35 The issuer is solely responsible for the ...
    09.04.19 - DGAP
    Hardman & Co Research: Global Pharmaceuticals: 2018 industry sales
    Hardman & Co Research Hardman & Co Research: Global Pharmaceuticals: 2018 industry sales 09-Apr-2019 / 16:10 GMT/BST
    21.01.19 - GlobeNewswire
    Sanofi UK marketing authorisation granted for Sanofi Pasteur’s Trivalent Influenza Vaccine (Split Virion, Inactivated) High Dose▼(TIV High Dose)
    Press Release Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) UK marketing authorisation granted for Sanofi Pasteur’s Trivalent Influenza Vaccine (Split Virion, Inactivated) ...
    03.02.15 - GlobeNewswire
    Sanofi : Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S.
    Sanofi : Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S. Sanofi and MannKind Announce Afrezza ® ,  the Only Inhaled Insulin, Now ...
    15.02.11 - ots
    The World Heart Federation, sanofi-aventis and Boehringer ...
    The World Heart Federation, sanofi-​aventis and Boehringer Ingelheim Announce Collaboration on Worldwide AF Awareness Campaign Geneva (ots/PRNewswire) - The World Heart ...
    05.11.10 - ots
    Sanofi-aventis Partners in European Atrial Fibrillation ...
    Sanofi-​aventis Partners in European Atrial Fibrillation Research Consortium Paris, November 5 (ots/PRNewswire) - Sanofi-​aventis announced today that it is a partner in a new ...
    29.10.10 - ots
    Covance und sanofi-aventis schliessen endgültiges ...
    Covance und sanofi-​aventis schliessen endgültiges Übereinkommen für 10-jährige strategische Zusammenarbeit im Bereich F&E Princeton, New Jersey (ots/PRNewswire) - ...
    26.10.10 - ots
    Sanofi-aventis Initiates Phase III Study with Teriflunomide ...
    Sanofi-​aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis Paris (ots/PRNewswire) - ...
    30.09.10 - ots
    Covance und Sanofi-Aventis unterzeichnen Vertrag über ...
    Covance und Sanofi-​Aventis unterzeichnen Vertrag über 10-jährige Zusammenarbeit im F&E-Bereich Princeton, New Jersey (ots/PRNewswire) - Covance Inc. gab heute die ...
    20.09.10 - ots
    Sanofi-aventis: Adding Lantus(R) to Oral Antidiabetic Drug ...
    Sanofi-​aventis: Adding Lantus(R) to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients With Type 2 Diabetes Paris (ots/PRNewswire) - Sanofi-​aventis ...
    20.09.10 - ots
    Sanofi-aventis: Investigational Compound Once-Daily ...
    Sanofi-​aventis: Investigational Compound Once-​Daily Lixisenatide Demonstrated Significant Improvement in Glucose Control in Patients With Type 2 Diabetes Paris ...
    31.03.10 - ots
    AgaMatrix und sanofi-aventis gehen weltweite Partnerschaft ...
    AgaMatrix und sanofi-​aventis gehen weltweite Partnerschaft im Bereich Diabetes ein Salem, New Hampshire, March 31, 2010 (ots/PRNewswire) - AgaMatrix, Inc. und sanofi-​aventis ...
    30.03.10 - ots
    Sanofi-aventis: Multaq(R) Receives Positive Recommendation ...
    Sanofi-​aventis: Multaq(R) Receives Positive Recommendation by NICE in New Appraisal Consultation Document Paris, March 30, 2010 (ots/PRNewswire) - Sanofi-​aventis ...

    Newssuche

    Videos

    newspaper
    26.04.24 +10,71%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »